Skip to main content
Fig. 2 | BMC Medical Genomics

Fig. 2

From: Truncated FRMD7 proteins in congenital Nystagmus: novel frameshift mutations and proteasomal pathway implications

Fig. 2

AB: The results of qPCR; Two groups of vectors showed no statistical difference in mRNA levels between the wild type and the mutants. C: Western-Blot results; The molecular weight of the mutant protein was significantly lower than that of the wild type. D: Results of the truncated protein degradation pathway assay. After the addition of the proteasome inhibitor MG-132, the truncated protein content increased significantly, demonstrating that both proteins were degraded via the ubiquitination pathway. (GFP: Green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase, serve as loading control; NC: Negative control; CQ: Chloroquine, a lysosome inhibitor; MG-132: Synonyms: Z-Leu-Leu-Leu-al, a proteasome inhibitor)

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us